-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Lineage Cell Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q2 2015 to Q2 2024.
- Lineage Cell Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending June 30, 2024 was 189M shares, a 10.7% increase year-over-year.
- Lineage Cell Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 173M shares, a 1.69% increase from 2022.
- Lineage Cell Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 170M shares.
- Lineage Cell Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2017 was 114M shares, a 15% increase from 2016.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)